Eli Lilly has launched "Employer Connect," offering a net price of $449 per month for the new multi-dose Zepbound. The program integrates with partners such as Teladoc Health and GoodRx to expand access to obesity medications. Novo-Nordisk A/S remains the primary competitor.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.